Literature DB >> 16003759

Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation.

Barbara Seliger1, Ulrike Ritz, Soldano Ferrone.   

Abstract

In humans as in other animal species, CD8+ cytotoxic T lymphocytes (CTLs) play an important if not the major role in controlling virus-infected and malignant cell growth. The interactions between CD8+ T cells and target cells are mediated by human leukocyte antigen (HLA) class I antigens loaded with viral and tumor antigen-derived peptides along with costimulatory receptor/ligand stimuli. Thus, to escape from CD8+ T-cell recognition and destruction, viruses and tumor cells have developed strategies to inhibit the expression and/or function of HLA class I antigens. In contrast, cells with downregulated MHC class I surface expression can be recognized by NK cells, although NK cell-mediated lysis could be abrogated by the expression of inhibiting NK cell receptors. This review discusses the molecular mechanisms utilized by viruses to inhibit the formation, transport and/or expression of HLA class I antigen/peptide complexes on the cell surface. The knowledge about viral interference with MHC class I antigen presentation is not only crucial to understand the pathogenesis of viral diseases, but contributes also to the design of novel strategies to counteract the escape mechanisms utilized by viruses. These investigations may eventually lead to the development of effective immunotherapies to control viral infections and virus-associated malignant diseases. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16003759     DOI: 10.1002/ijc.21312

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  47 in total

1.  Prognostic significance of HLA class I expressing in gastric carcinoma defined by monoclonal anti-pan HLA class I antibody, EMR8-5.

Authors:  Hae-Wan Lee; Soo Kee Min; Young-Su Ju; Joohon Sung; Man Sup Lim; Dae Hyun Yang; Bong Hwa Lee
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

2.  Pancreatic beta cells persistently infected with coxsackievirus B4 are targets of NK cell-mediated cytolytic activity.

Authors:  Magloire Pandoua Nekoua; Antoine Bertin; Famara Sane; Enagnon Kazali Alidjinou; Delphine Lobert; Jacques Trauet; Christine Hober; Ilka Engelmann; Kabirou Moutairou; Akadiri Yessoufou; Didier Hober
Journal:  Cell Mol Life Sci       Date:  2019-06-06       Impact factor: 9.261

3.  NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Authors:  Sylvie Rusakiewicz; Aurélie Perier; Michaela Semeraro; Jonathan M Pitt; Elke Pogge von Strandmann; Katrin S Reiners; Sandrine Aspeslagh; Christelle Pipéroglou; Frédéric Vély; Alexandre Ivagnes; Sarah Jegou; Niels Halama; Loic Chaigneau; Pierre Validire; Christos Christidis; Thierry Perniceni; Bruno Landi; Anne Berger; Nicolas Isambert; Julien Domont; Sylvie Bonvalot; Philippe Terrier; Julien Adam; Jean-Michel Coindre; Jean-François Emile; Vichnou Poirier-Colame; Kariman Chaba; Benedita Rocha; Anne Caignard; Antoine Toubert; David Enot; Joachim Koch; Aurélien Marabelle; Marion Lambert; Sophie Caillat-Zucman; Serge Leyvraz; Christian Auclair; Eric Vivier; Alexander Eggermont; Christophe Borg; Jean-Yves Blay; Axel Le Cesne; Olivier Mir; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

4.  Inhibition of antigen presentation during AAV gene therapy using virus peptides.

Authors:  Wenwei Shao; Xiaojing Chen; Richard J Samulski; Matthew L Hirsch; Chengwen Li
Journal:  Hum Mol Genet       Date:  2018-02-15       Impact factor: 6.150

Review 5.  Emerging Opportunities and Challenges in Cancer Immunotherapy.

Authors:  Theresa L Whiteside; Sandra Demaria; Maria E Rodriguez-Ruiz; Hassane M Zarour; Ignacio Melero
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

6.  Human cytomegalovirus (HCMV) US2 protein interacts with human CD1d (hCD1d) and down-regulates invariant NKT (iNKT) cell activity.

Authors:  Jihye Han; Seung Bae Rho; Jae Yeon Lee; Joonbeom Bae; Se Ho Park; Suk Jun Lee; Sang Yeol Lee; Curie Ahn; Jae Young Kim; Taehoon Chun
Journal:  Mol Cells       Date:  2013-11-08       Impact factor: 5.034

7.  Amyloid precursor-like protein 2 association with HLA class I molecules.

Authors:  Amit Tuli; Mahak Sharma; Xiaojian Wang; Laura C Simone; Haley L Capek; Steven Cate; William H Hildebrand; Naava Naslavsky; Steve Caplan; Joyce C Solheim
Journal:  Cancer Immunol Immunother       Date:  2009-01-31       Impact factor: 6.968

8.  Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.

Authors:  Paolo Carrega; Gaetana Pezzino; Paola Queirolo; Irene Bonaccorsi; Michela Falco; Giuseppe Vita; Daniela Pende; Aldo Misefari; Alessandro Moretta; Maria Cristina Mingari; Lorenzo Moretta; Guido Ferlazzo
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

Review 9.  Therapeutic cancer vaccines in combination with conventional therapy.

Authors:  Mads Hald Andersen; Niels Junker; Eva Ellebaek; Inge Marie Svane; Per Thor Straten
Journal:  J Biomed Biotechnol       Date:  2010-06-29

10.  Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand.

Authors:  William R Frazier; Noriko Steiner; Lihua Hou; Sivanesan Dakshanamurthy; Carolyn Katovich Hurley
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.